The results are presented as the percentage of patients achieving normoprolactinemia, the number of cases reporting a change in tumor size, the mean of the magnitude of change in prolactin levels, the percentage of patients showing improvement or resolution of symptoms, and the association of estrogen receptor subtype with treatment outcome. This evidence concerns the gene PRL and neoplasm.